Success Metrics

Active Trials
6(100%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting3
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
6
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

recruiting350%
active_not_recruiting350%

Recent Activity

6 active trials
Showing 5 of 6
recruitingphase_3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292
recruitingphase_2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702
active_not_recruitingphase_3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473
active_not_recruitingphase_2

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
recruitingphase_2

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07325292Phase 3

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Recruiting
NCT06500702Phase 2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Recruiting
NCT06141473Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Active Not Recruiting
NCT06111586Phase 2

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

Active Not Recruiting
NCT07412470Phase 2

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Recruiting
NCT06141486Phase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Active Not Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6